We are live on ! Find out more
TECH icon

Bio-Techne

294 hedge funds and large institutions have $3.93B invested in Bio-Techne in 2016 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 95 increasing their positions, 113 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

47% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 19

17% more call options, than puts

Call options by funds: $292K | Put options by funds: $249K

2% more funds holding

Funds holding: 288294 (+6)

6% less capital invested

Capital invested by funds: $4.19B → $3.93B (-$256M)

16% less repeat investments, than reductions

Existing positions increased: 95 | Existing positions reduced: 113

40% less funds holding in top 10

Funds holding in top 10: 53 (-2)

Holders
294
Holders Change
+6
Holders Change %
+2.08%
% of All Funds
7.82%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.08%
New
28
Increased
95
Reduced
113
Closed
19
Calls
$292K
Puts
$249K
Net Calls
+$43K
Net Calls Change
-$192K

TECH Hedge Fund Activity: Q3 2016 in Review

294 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Bio-Techne (TECH) for Q3 2016, worth a combined $3.93B — down 6.1% from $4.19B a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new TECH positions and 19 closed out — a net gain of 9 holders — while 95 added to existing stakes and 113 trimmed.

The largest buyer was Fred Alger Management, adding an estimated $21.1M. The largest seller was Jackson Square Partners, cutting an estimated $81M.

  • 294 institutional investors held Bio-Techne (TECH) as of Q3 2016, up from 288 in Q2 2016.
  • Funds reported $3.93B of Bio-Techne stock for Q3 2016, down 6.1% quarter-over-quarter.
  • 28 funds opened new Bio-Techne positions in Q3 2016 and 19 closed out, a net change of +9 holders.
  • The largest Bio-Techne buyer in Q3 2016 was Fred Alger Management, an estimated $21.1M added.
  • The largest Bio-Techne seller in Q3 2016 was Jackson Square Partners, an estimated $81M sold.

Based on aggregated 13F filings for Q3 2016.